Glaxosmithkline Intellectual Property Development Limited

Glaxo Group Limited

Tejinder Kaur Bhinder

Alan Peter Lewis

Martin Orecchia

Laura Hook

Steven Grant

Chika Akinseye

Qing Shan Zhang

Volker Germaschewski

Mark Brian Pepys

Susannah Karen Ford

Radha Shah Parmar

Wenqing Jiang

Liuqing Yang

Yangsheng Qiu

Yingli Ma

Guhan Nagappan

Yanjiao Zhou

Chong Ding

Xu Feng

Li Cui

The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins

The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Biopharmaceutical compositions comprising antibody variants

The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Binding agonist for treatment of neurological and other disorders

Biopharmaceutical compositions and related methods

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

Antigen binding proteins

Growing community of inventors

Stevenage, United Kingdom

Tejinder Kaur Bhinder